Hybrid Delivery System Boosts DNA Vaccines Potential

Researchers at the University at Buffalo have developed a hybrid delivery system designed to fight cancer, HIV, flu, and other diseases Scientists from the University at Buffalo have created a novel hybrid system designed to deliver genetic antigens and elicit a strong immune response in patients, something DNA vaccines have so far failed to deliver. The hybrid, presented in the …

GSK Statement on First Phase 1 Trial Results of a Candidate Ebola Vaccine

November 24, 2014 First results from a small phase 1 trial published today in the New England Journal of Medicine show that a GSK/NIH Ebola candidate vaccine was well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the USA who received it. The candidate vaccine used in the trial conducted by the National Institutes …

Merck enters the Ebola Vaccine Race in NewLink Partnership

Merck obtains the rights to NewLink genetics’ experimental Ebola Vaccine, putting pressure on GSK Merck has struck a agreement with NewLink Genetics to licence their investigational Ebola vaccine, rVSV-EBOV. The $50 million agreement gives Merck exclusive rights to develop, manufacture, and distribute the vaccine across the world. This partnership should allow NewLink to keep pace with the huge effort by …

Integral Molecular Announces Patent Allowance for Dengue Research Technology

July 17, 2014 Integral Molecular, a leader in membrane protein research, announces the issuance of a new composition patent protecting dengue reporter virus particles (RVPs). The invention relates to the company’s chimeric and codon-optimized flavivirus replicons, expression plasmids, and RVPs used for infectivity, neutralization, enhancement and structure-function studies of dengue virus (DENV) and its envelope protein (prM/E). U.S. Patent No …

Download presentation: NIAID Resources and Opportunities for Vaccine Research

In November 2012 over 200 delegates participated in the 13th Annual World Vaccine Congress Lyon in France. This event brings together vaccine leaders and policy makers from around the globe. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Cristina Cassetti, Ph.D, Program Officer, Division of Microbiology and Infectious Diseases, National Institute of …

Ineffective – HVTN 505 HIV Vaccine Trial Discontinued

The National Institute of Allergy and Infectious Diseases (NIAID) has announced that it will halt its HVTN 505 HIV vaccine trial due to a perceived lack of efficacy. A scheduled review by an independent data and safety monitoring board found that the vaccine regimen neither prevented HIV infection nor reduced viral load in vaccine recipients who became infected with HIV. …

Download: NIAID Influenza vaccine development

Want to know more? Why not download the full presentation about NIAID Influenza vaccine development: Informed by rapid responses to viral outbreaks How has NIAID responded to support pandemic and seasonal influenza preparedness? What are NIAIDs preclinical resources and clinical trial infrastructure capabilities for influenza response? What future areas have been identified for NIAID preclinical and clinical support? Dr David …